The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The FDA has released a new draft guidance focused on using minimal residual disease (MRD) and complete response (CR) as primary endpoints in multiple myeloma trials.
The second session of the Community Oncology Brown Bag Series hosted by SOHO Insider featured guest speaker Tara Graff, DO, an oncologist at Mission Cancer + Blood and director of their clinical research program.
Bor-Sheng Ko, MD, PhD, Associate Professor at National Taiwan University College of Medicine and President of the Hematology Society of Taiwan, discusses the historic significance of bringing the Society of Hematologic Oncology to the Asia-Pacific region.
Live session held on February 11, 2026, from 2:00–2:30 PM CST with speaker Tara Graff presenting on “Implementing Bispecific Antibodies in Community Practice.”
In this video from SOHO Asia 2026, Dr. DiPersio discusses highlights from the acute myeloid leukemia session with Drs. Andrew Wei, Naval Daver, and Richard Dillon. Dr. DiPersio particularly focuses on how to use MRD to follow patients to make treatment decisions and
provides his own take on the topic.
To access the SOHO Career Center click the following link.
